91 related articles for article (PubMed ID: 4040805)
1. Biliary excretion of platinum in rats after administration of cisplatin and aqua(1,1-bis(aminomethyl)-cyclohexane)sulfatoplatinum(II) (spiroplatin, TNO-6).
Van der Vijgh WJ; Verbeek PC; Klein I; Pinedo HM
Cancer Lett; 1985 Aug; 28(1):103-9. PubMed ID: 4040805
[TBL] [Abstract][Full Text] [Related]
2. Influence of hydrolysis products of aqua(1,1-bis(aminomethyl)cyclohexane)sulfatoplatinum(II) on toxicity in rats.
Elferink F; Van der Vijgh WJ; Van der Poort SE; Henzen-Logmans SC; Pinedo HM
Cancer Lett; 1984 Nov; 25(1):61-9. PubMed ID: 6542826
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
van der Vijgh WJ; Elferink F; Vermorken JB; ten Bokkel Huinink WW; Klein I; Gall HE; Simonetti G; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):621-7. PubMed ID: 3383966
[TBL] [Abstract][Full Text] [Related]
4. Toxicology and pharmacokinetics of (1,1-bis(aminomethyl)cyclohexane)oxalatoplatinum(II) (TNO-38).
Lelieveld P; van der Vijgh WJ; van Velzen D
Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1467-73. PubMed ID: 3595672
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (I), and cis-dichloro-bis-cyclopropylamine platinum (II).
Harrison R; McAuliffe CA; Zaki A; Baer J; Sharma H; Smith A; Jackson H; Fox BW
Cancer Chemother Pharmacol; 1983; 10(2):90-5. PubMed ID: 6682017
[No Abstract] [Full Text] [Related]
6. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
Siddik ZH; Newell DR; Boxall FE; Harrap KR
Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
[TBL] [Abstract][Full Text] [Related]
7. Analysis of antitumour [1,1-bis(aminomethyl)cyclohexane]platinum(II) complexes derived from spiroplatin by high-performance liquid chromatography with differential pulse amperometric detection.
Elferink F; van der Vijgh WJ; Pinedo HM
J Chromatogr; 1985 Mar; 320(2):379-92. PubMed ID: 4030937
[TBL] [Abstract][Full Text] [Related]
8. Preclinical toxicology of platinum analogues in dogs.
Lelieveld P; van der Vijgh WJ; van Velzen D
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1147-54. PubMed ID: 3308482
[TBL] [Abstract][Full Text] [Related]
9. Uptake of platinum compounds in human tumors. In vitro study.
Hecquet B; Leroy A; Lefebvre JL; Peyrat JP; Adenis L
Bull Cancer; 1986; 73(5):535-41. PubMed ID: 3535936
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II).
Lautersztain J; Perez-Soler R; Khokhar AR; Newman RA; Lopez-Berestein G
Cancer Chemother Pharmacol; 1986; 18(2):93-7. PubMed ID: 3791565
[TBL] [Abstract][Full Text] [Related]
11. Liver organotropism and biotransformation of a novel platinum-ursodeoxycholate derivative, Bamet-UD2, with enhanced antitumour activity.
Larena MG; Martinez-Diez MC; Monte MJ; Dominguez MF; Pascual MJ; Marin JJ
J Drug Target; 2001 Jun; 9(3):185-200. PubMed ID: 11697204
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
13. Dithiocarbamate-induced biliary platinum excretion and the control of cis-platinum nephrotoxicity.
Basinger MA; Jones MM; Gilbreath SG; Walker EM; Fody EP; Mayhue MA
Toxicol Appl Pharmacol; 1989 Feb; 97(2):279-88. PubMed ID: 2538006
[TBL] [Abstract][Full Text] [Related]
14. Biliary excretion of platinum in a patient treated with cis-dichlorodiammineplatinum (II).
Shelley MD; Fish RG; Adams M
Antimicrob Agents Chemother; 1985 Feb; 27(2):275-6. PubMed ID: 4039121
[TBL] [Abstract][Full Text] [Related]
15. Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice.
Boven E; Nauta MM; Schluper HM; Elferink F; van der Vijgh WJ; Pinedo HM
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1253-60. PubMed ID: 4076289
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive estimation of bound and mobile platinum compounds in the kidney using a radiopharmacokinetic model.
Brechner RR; D'Argenio DZ; Dahalan R; Wolf W
J Pharm Sci; 1986 Sep; 75(9):873-7. PubMed ID: 3783454
[TBL] [Abstract][Full Text] [Related]
17. Nephrotoxicity of 1,1-diaminomethylcyclohexane sulphato platinum II (spiroplatin; TNO-6).
Offerman JJ; Meijer S; Mulder NH; Sleijfer DT; Bijster P; Hellendoorn HB; Donker AJ; van der Hem GK
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):447-51. PubMed ID: 3891361
[TBL] [Abstract][Full Text] [Related]
18. Atypical pharmacokinetics and excretion of new platinum analogues in rodents.
Webster LK; Ellis AG; Apicella C; Deacon GB
Cancer Chemother Pharmacol; 2002 Jan; 49(1):87-92. PubMed ID: 11855757
[TBL] [Abstract][Full Text] [Related]
19. Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives.
Lelieveld P; Van der Vijgh WJ; Veldhuizen RW; Van Velzen D; Van Putten LM; Atassi G; Danguy A
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1087-104. PubMed ID: 6381064
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
